Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …

Considerable efforts have been exerted to implement Pharmacogenomics (PGx), the study
of interindividual variations in DNA sequence related to drug response, into routine clinical …

Individual variability in drug response (IVDR) can be a major cause of adverse drug
reactions (ADRs) and prolonged therapy, resulting in a substantial health and economic …

Thoughtful integration of interruptive clinical decision support (CDS) alerts within the
electronic health record is essential to guide clinicians on the application of …

Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among
adults and are more common in multimorbid patients, worsening clinical outcomes and …

Purpose Personalized pharmacotherapy, including for the pediatric population, provides
optimal treatment and has emerged as a major trend owing to advanced drug therapeutics …

This white paper was prepared by the Global Alliance for Genomics and Health Regulatory
and Ethics Work Stream's Pediatric Task Team to review and provide perspective with …

Introduction: The practice of informed consent (IC) for pharmacogenomic testing in clinical
settings varies, and there is currently no consensus on which elements of IC to provide to …

Introduction: While pharmacogenomic (PGx) testing is routine in urban healthcare
institutions or academic health centers with access to existing expertise, uptake in medically …

Aim: Pre-emptive testing of pharmacogenomic (PGx) variations has potential to improve
medication safety and effectiveness; however, testing is not routine. Given the newfound …